Lantheus is trading 20.51% down now at $79.49 in after-hours trading amid renewed antitrust scrutiny of its planned Curium acquisition. - Curium withdrew and refiled the Hart-Scott-Rodino notice, restarting a 30-day FTC review period scheduled to expire October 21, 2026. - Lantheus announced final FDA approval for Bravnetsa on September 22, but the development has not offset merger-related concerns.